Mateon Therapeutics, Inc. (OTCMKTS:MATN – Get Free Report)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.03 and traded as high as $0.04. Mateon Therapeutics shares last traded at $0.04, with a volume of 5,025 shares trading hands.
Mateon Therapeutics Stock Performance
The company has a 50 day moving average of $0.03 and a 200-day moving average of $0.03.
Mateon Therapeutics Company Profile
Mateon Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications. The company's lead product candidate is OT-101, an antisense against TGF-beta, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
Featured Stories
- Five stocks we like better than Mateon Therapeutics
- Dividend Capture Strategy: What You Need to Know
- Why Genuine Parts Company Is a Royally Good Buy Right Now
- What is a Dividend King?
- Industrials Are Quietly Outpacing the Market: 3 Stocks to Watch
- Buy P&G Now, Before It Sets A New All-Time High
- These 5 Energy Stocks Hedge Inflation With Growth Potential
Receive News & Ratings for Mateon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mateon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}
